journal article·2023-02Open access

Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection

Jingran Chen, Ying Li, Zhen Liu

Cell Reports Physical Science· Volume 4· Issue 2

Abstract

The COVID-19 pandemic has posed a severe threat to human life and the global economy. Although conventional treatments, including vaccines, antibodies, and small-molecule inhibitors, have been broadly developed, they usually fall behind the constant mutation of SARS-CoV-2, due to the long screening process and high production cost. Functional nucleic acid (FNA)-based therapeutics are a newly emerging promising means against COVID-19, considering their timely adaption to different mutants and easy design for broad-spectrum virus inhibition. In this review, we survey typical FNA-related therapeutics against SARS-CoV-2 infection, including aptamers, aptamer-integrated DNA frameworks, functional RNA, and CRISPR-Cas technology. We first introduce the pathogenesis, transmission, and evolution of SARS-CoV-2, then analyze the existing therapeutic and prophylactic strategies, including their pros and cons. Subsequently, the FNAs are recommended as potent alternative therapeutics from their screening process and controllable engineering to effective neutralization. Finally, we put forward the remaining challenges of the existing field and sketch out the future development directions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · SARS-CoV-2 detection and testing · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 200310.1016/S0140-6736(03)14630-2 ↗
2. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia10.1056/NEJMoa1211721 ↗
3. SARS and MERS: recent insights into emerging coronaviruses10.1038/nrmicro.2016.81 ↗
4. Characteristics of SARS-CoV-2 and COVID-1910.1038/s41579-020-00459-7 ↗
5. Neutralizing antibodies for the prevention and treatment of COVID-1910.1038/s41423-021-00752-2 ↗
6. The COVID-19 pandemic10.1080/10408363.2020.1783198 ↗
7. Functional nucleic acids as modular components against SARS-CoV-2: from diagnosis to therapeutics10.1016/j.bios.2021.113944 ↗
8. Aptamers—diagnostic and therapeutic solution in SARS-CoV-210.3390/ijms23031412 ↗
9. Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19
10. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection10.1002/anie.202100225 ↗
11. Discovery of aptamers targeting the receptor-binding domain of the SARS-CoV-2 spike glycoprotein10.1021/acs.analchem.0c01394 ↗
12. Spherical neutralizing aptamer inhibits SARS-CoV-2 infection and suppresses mutational escape10.1021/jacs.1c08226 ↗
13. Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape10.1016/j.nantod.2022.101499 ↗
14. Neutralizing aptamers block S/RBD-ACE2 interactions and prevent host cell infection10.1002/anie.202100345 ↗
15. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 110.1038/s41392-021-00649-6 ↗
16. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry10.1073/pnas.2112942118 ↗
17. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation10.1016/S2666-5247(21)00068-9 ↗
18. A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection by an RBD-independent mechanism10.1002/anie.202100316 ↗
19. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD-independent or dependent approach10.7150/thno.74428 ↗
20. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike10.1126/sciadv.aav4580 ↗
21. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion10.1038/s41422-020-0305-x ↗
22. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-210.1126/science.abc6952 ↗
23. A topology-matching spike protein-capping tetrahedral DNA nanocrown for SARS-CoV-2 neutralization10.31635/ccschem.022.202101780 ↗
24. High mannose-specific aptamers for broad-spectrum virus inhibition and cancer targeting10.31635/ccschem.021.202101672 ↗
25. Discovery of indole-modified aptamers for highly specific recognition of protein glycoforms10.1038/s41467-021-26933-1 ↗
26. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection10.3390/v6031294 ↗
27. An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells10.1371/journal.pone.0097574 ↗
28. Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus10.1089/nat.2011.0321 ↗
29. A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure10.7150/thno.30972 ↗
30. Aptamer blocking S-TLR4 interaction selectively inhibits SARS-CoV-2 induced inflammation10.1038/s41392-022-00968-2 ↗
31. Aptamers against pro- and anti-inflammatory cytokines: a review10.1007/s10753-016-0477-1 ↗
32. Aptamers against immunologic targets: diagnostic and therapeutic prospects10.1089/nat.2015.0568 ↗
33. Identification of G-quadruplex anti-Interleukin-2 aptamer with high specificity through SELEX stringency10.1016/j.heliyon.2022.e09721 ↗
34. The cytokine storm of severe influenza and development of immunomodulatory therapy10.1038/cmi.2015.74 ↗
35. Perspectives on SARS-CoV-2 main protease inhibitors10.1021/acs.jmedchem.1c00409 ↗
36. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease10.1126/science.abb4489 ↗
37. De novo ssRNA aptamers against the SARS-CoV-2 main protease: in silico design and molecular dynamics simulation10.3390/ijms22136874 ↗
38. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase10.1016/j.bbrc.2007.12.020 ↗
39. Aptamer BC 007 - efficient binder of spreading-crucial SARS-CoV-2 proteins10.1016/j.heliyon.2020.e05421 ↗
40. Aptamer BC 007’s affinity to specific and less-specific anti-SARS-CoV-2 neutralizing antibodies10.3390/v13050932 ↗
41. Selecting aptamers for a glycoprotein through the incorporation of the boronic acid moiety10.1021/ja801510d ↗
42. Qin · 2021
43. In vivo selection of tumor-targeting RNA motifs10.1038/nchembio.277 ↗
44. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents10.1038/mtna.2014.49 ↗
45. Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development10.1016/j.biotechadv.2018.11.001 ↗
46. De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants10.1126/sciadv.abq6207 ↗
47. Aptamers against viruses: selection strategies and bioanalytical applications10.1016/j.trac.2021.116349 ↗
48. High-affinity RNA aptamers against the HIV-1 protease inhibit both in vitro protease activity and late events of viral replication10.1038/mtna.2015.1 ↗
49. Designer DNA architecture offers precise and multivalent spatial pattern-recognition for viral sensing and inhibition10.1038/s41557-019-0369-8 ↗
50. Programmable icosahedral shell system for virus trapping10.1038/s41563-021-01020-4 ↗
51. Broad-spectrum virus trapping with heparan sulfate-modified DNA origami shells10.1021/acsnano.1c11328 ↗
52. Spatially patterned neutralizing icosahedral DNA nanocage for efficient SARS-CoV-2 blocking10.1021/jacs.2c02764 ↗
53. Net-shaped DNA nanostructures designed for rapid/sensitive detection and potential inhibition of the SARS-CoV-2 virus
54. Spatial- and valence-matched neutralizing DNA nanostructure blocks wild-type SARS-CoV-2 and omicron variant infection10.1021/acsnano.2c06803 ↗
55. In situ covalent functionalization of DNA origami virus-like particles10.1021/acsnano.1c03158 ↗
56. Role of nanoscale antigen organization on B-cell activation probed using DNA origami10.1038/s41565-020-0719-0 ↗
57. Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds
58. DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response
59. Elucidating the effect of nanoscale receptor-binding domain organization on SARS-CoV-2 infection and immunity activation with DNA origami10.1021/jacs.2c09229 ↗
60. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro10.1038/s41467-022-30546-7 ↗
61. Efficient inhibition of SARS-CoV-2 using chimeric antisense oligonucleotides through RNase L activation10.1002/anie.202105942 ↗
62. Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes10.1016/j.jconrel.2022.03.051 ↗
63. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-1910.1016/j.ymthe.2021.05.004 ↗
64. A lysosome-activated tetrahedral nanobox for encapsulated siRNA delivery10.1002/adma.202201731 ↗
65. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation10.1111/all.14850 ↗
66. Inhibition of SARS-CoV-2 replication by a small interfering RNA targeting the leader sequence10.3390/v13102030 ↗
67. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread10.1093/nar/gkab1248 ↗
68. Suppression of SARS-CoV-2 replication with stabilized and click-chemistry modified siRNAs10.1002/anie.202204556 ↗
69. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant10.15252/emmm.202115298 ↗
70. MicroRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-1910.1007/s40265-021-01474-5 ↗
71. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review10.1016/j.meegid.2021.104832 ↗
72. Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs10.1093/nar/gkab1096 ↗
73. CRISPR-Cas guides the future of genetic engineering10.1126/science.aat5011 ↗
74. Unravelling the structural and mechanistic basis of CRISPR–Cas systems10.1038/nrmicro3279 ↗
75. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza10.1016/j.cell.2020.04.020 ↗
76. A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses10.1016/j.xcrm.2021.100245 ↗
77. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders10.1021/acscentsci.0c00984 ↗
78. Viral targets for vaccines against COVID-1910.1038/s41577-020-00480-0 ↗
79. Advances in gene-based vaccine platforms to address the COVID-19 pandemic10.1016/j.addr.2021.01.003 ↗
80. A systematic review of SARS-CoV-2 vaccine candidates10.1038/s41392-020-00352-y ↗
81. A bivalent omicron-containing booster vaccine against covid-1910.1056/NEJMoa2208343 ↗
82. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial10.1038/s41591-022-02031-7 ↗
83. Neutralization of omicron subvariant BA.2.75 after bivalent vaccination10.1056/NEJMc2212772 ↗
84. SARS-CoV-2 pathogenesis10.1038/s41579-022-00713-0 ↗
85. Mechanisms of SARS-CoV-2 transmission and pathogenesis10.1016/j.it.2020.10.004 ↗
86. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing10.1038/s41586-020-2286-9 ↗
87. Structures and distributions of SARS-CoV-2 spike proteins on intact virions10.1038/s41586-020-2665-2 ↗
88. Site-specific glycan analysis of the SARS-CoV-2 spike10.1126/science.abb9983 ↗
89. Mechanisms of SARS-CoV-2 entry into cells10.1038/s41580-021-00418-x ↗
90. Cytokine release syndrome in severe COVID-1910.1126/science.abb8925 ↗
91. COVID-19 cytokine storm: the interplay between inflammation and coagulation10.1016/S2213-2600(20)30216-2 ↗
92. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes10.1016/j.cell.2020.11.025 ↗
93. Updated approaches against SARS-CoV-210.1128/AAC.00483-20 ↗
94. Neutralizing monoclonal antibodies for treatment of COVID-1910.1038/s41577-021-00542-x ↗
95. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants10.1016/j.celrep.2022.110812 ↗
96. Effective treatment of severe COVID-19 patients with tocilizumab10.1073/pnas.2005615117 ↗
97. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants10.1016/j.virs.2022.02.005 ↗
98. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-1910.1126/science.abl4784 ↗
99. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis10.1038/s41594-021-00651-0 ↗
100. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2